Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure. 2002

Lynne E Wagoner, and Laura L Craft, and Paul Zengel, and Nancy McGuire, and Deborah A Rathz, and Gerald W Dorn, and Stephen B Liggett
Department of Cardiology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0564, USA.

BACKGROUND Exercise performance in patients with congestive heart failure is partially dependent on cardiac beta1-adrenergic receptor (beta1AR) function. There are 2 common polymorphisms of the beta1AR gene that alter the encoded amino acids at positions 49 (Ser or Gly) and 389 (Gly or Arg) and alter receptor function in vitro. Their relevance to modification of cardiac function in heart failure is not known. METHODS Exercise testing was performed in 263 patients with idiopathic or ischemic cardiomyopathy (left ventricular ejection fraction approximately 25%). Potential associations were sought between beta1AR genotypes and the primary outcome variables of peak oxygen consumption (VO2), heart rate response, and exercise time. RESULTS The major determinants of exercise capacity were the polymorphisms at position 389, where patients homozygous for Gly389 had significantly lower peak VO2 compared with those with Arg389 (14.5 +/- 0.6 vs 17.7 +/- 0.4 mL/kg/min, P =.006), despite similar clinical characteristics including left ventricular ejection fraction. Consistent with a gene dose-response, heterozygosity was associated with an intermediate response (16.9 +/- 0.6 mL/kg/min, P <.05). When position 49 genotypes were included, a graded relationship between the 5 2-locus haplotypes and VO2 was found. Two haplotypes displayed the most divergent peak VO2: homozygous Gly389/Ser49, and homozygous Arg389/Gly49 carriers (14.4 +/- 0.5 vs 18.2 +/- 0.8 mL/kg/min, P =.001). Genotype did not predict the heart rate response. The above results were independent of beta-blocker or other medication use, left ventricular ejection fraction, beta2AR genotype, or other demographic and clinical characteristics. CONCLUSIONS beta1AR polymorphisms are a significant determinant of exercise capacity in patients with congestive heart failure. Early identification, by genetic testing for these polymorphisms, of heart failure patients at risk for development of depressed exercise capacity may be useful for initiation of specific therapy tailored to genotype.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010101 Oxygen Consumption The rate at which oxygen is used by a tissue; microliters of oxygen STPD used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (Stedman, 25th ed, p346) Consumption, Oxygen,Consumptions, Oxygen,Oxygen Consumptions
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D002311 Cardiomyopathy, Dilated A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein. Cardiomyopathy, Congestive,Congestive Cardiomyopathy,Dilated Cardiomyopathy,Cardiomyopathy, Dilated, 1a,Cardiomyopathy, Dilated, Autosomal Recessive,Cardiomyopathy, Dilated, CMD1A,Cardiomyopathy, Dilated, LMNA,Cardiomyopathy, Dilated, With Conduction Defect 1,Cardiomyopathy, Dilated, with Conduction Deffect1,Cardiomyopathy, Familial Idiopathic,Cardiomyopathy, Idiopathic Dilated,Cardiomyopathies, Congestive,Cardiomyopathies, Dilated,Cardiomyopathies, Familial Idiopathic,Cardiomyopathies, Idiopathic Dilated,Congestive Cardiomyopathies,Dilated Cardiomyopathies,Dilated Cardiomyopathies, Idiopathic,Dilated Cardiomyopathy, Idiopathic,Familial Idiopathic Cardiomyopathies,Familial Idiopathic Cardiomyopathy,Idiopathic Cardiomyopathies, Familial,Idiopathic Cardiomyopathy, Familial,Idiopathic Dilated Cardiomyopathies,Idiopathic Dilated Cardiomyopathy
D005260 Female Females
D005819 Genetic Markers A phenotypically recognizable genetic trait which can be used to identify a genetic locus, a linkage group, or a recombination event. Chromosome Markers,DNA Markers,Markers, DNA,Markers, Genetic,Genetic Marker,Marker, Genetic,Chromosome Marker,DNA Marker,Marker, Chromosome,Marker, DNA,Markers, Chromosome
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006579 Heterozygote An individual having different alleles at one or more loci regarding a specific character. Carriers, Genetic,Genetic Carriers,Carrier, Genetic,Genetic Carrier,Heterozygotes
D006720 Homozygote An individual in which both alleles at a given locus are identical. Homozygotes

Related Publications

Lynne E Wagoner, and Laura L Craft, and Paul Zengel, and Nancy McGuire, and Deborah A Rathz, and Gerald W Dorn, and Stephen B Liggett
January 2010, Heart failure clinics,
Lynne E Wagoner, and Laura L Craft, and Paul Zengel, and Nancy McGuire, and Deborah A Rathz, and Gerald W Dorn, and Stephen B Liggett
May 2012, Arquivos brasileiros de cardiologia,
Lynne E Wagoner, and Laura L Craft, and Paul Zengel, and Nancy McGuire, and Deborah A Rathz, and Gerald W Dorn, and Stephen B Liggett
October 2002, The New England journal of medicine,
Lynne E Wagoner, and Laura L Craft, and Paul Zengel, and Nancy McGuire, and Deborah A Rathz, and Gerald W Dorn, and Stephen B Liggett
October 2006, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
Lynne E Wagoner, and Laura L Craft, and Paul Zengel, and Nancy McGuire, and Deborah A Rathz, and Gerald W Dorn, and Stephen B Liggett
October 2013, Sheng li ke xue jin zhan [Progress in physiology],
Lynne E Wagoner, and Laura L Craft, and Paul Zengel, and Nancy McGuire, and Deborah A Rathz, and Gerald W Dorn, and Stephen B Liggett
November 2008, Revista medica de Chile,
Lynne E Wagoner, and Laura L Craft, and Paul Zengel, and Nancy McGuire, and Deborah A Rathz, and Gerald W Dorn, and Stephen B Liggett
June 1999, Proceedings of the National Academy of Sciences of the United States of America,
Lynne E Wagoner, and Laura L Craft, and Paul Zengel, and Nancy McGuire, and Deborah A Rathz, and Gerald W Dorn, and Stephen B Liggett
March 2006, European journal of heart failure,
Lynne E Wagoner, and Laura L Craft, and Paul Zengel, and Nancy McGuire, and Deborah A Rathz, and Gerald W Dorn, and Stephen B Liggett
March 2006, Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova,
Lynne E Wagoner, and Laura L Craft, and Paul Zengel, and Nancy McGuire, and Deborah A Rathz, and Gerald W Dorn, and Stephen B Liggett
June 2004, Clinical cardiology,
Copied contents to your clipboard!